PL4054620T3 - Semaglutyd w leczeniu demencji alzheimera - Google Patents

Semaglutyd w leczeniu demencji alzheimera

Info

Publication number
PL4054620T3
PL4054620T3 PL20803489.2T PL20803489T PL4054620T3 PL 4054620 T3 PL4054620 T3 PL 4054620T3 PL 20803489 T PL20803489 T PL 20803489T PL 4054620 T3 PL4054620 T3 PL 4054620T3
Authority
PL
Poland
Prior art keywords
semaglutide
dementia
alzheimer
treatment
Prior art date
Application number
PL20803489.2T
Other languages
English (en)
Polish (pl)
Inventor
Sarah FRIEDRICH
Charlotte Christine Thim HANSEN
Lotte Bjerre Knudsen
Anna SECHER
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73172681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4054620(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of PL4054620T3 publication Critical patent/PL4054620T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL20803489.2T 2019-11-06 2020-11-05 Semaglutyd w leczeniu demencji alzheimera PL4054620T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19207501 2019-11-06
EP20186623 2020-07-20
PCT/EP2020/081087 WO2021089678A1 (en) 2019-11-06 2020-11-05 Glp-1 receptor agonists in dementia

Publications (1)

Publication Number Publication Date
PL4054620T3 true PL4054620T3 (pl) 2024-10-14

Family

ID=73172681

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20803489.2T PL4054620T3 (pl) 2019-11-06 2020-11-05 Semaglutyd w leczeniu demencji alzheimera

Country Status (19)

Country Link
US (4) US20220280612A1 (cg-RX-API-DMAC7.html)
EP (2) EP4054620B1 (cg-RX-API-DMAC7.html)
JP (2) JP7670698B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220110731A (cg-RX-API-DMAC7.html)
CN (1) CN114728042A (cg-RX-API-DMAC7.html)
AU (1) AU2020377469A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022007721A2 (cg-RX-API-DMAC7.html)
CA (1) CA3154744A1 (cg-RX-API-DMAC7.html)
ES (1) ES2984177T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241052T1 (cg-RX-API-DMAC7.html)
HU (1) HUE067514T2 (cg-RX-API-DMAC7.html)
IL (1) IL291876A (cg-RX-API-DMAC7.html)
MA (1) MA57599B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022004779A (cg-RX-API-DMAC7.html)
PH (1) PH12022550842A1 (cg-RX-API-DMAC7.html)
PL (1) PL4054620T3 (cg-RX-API-DMAC7.html)
RS (1) RS65780B1 (cg-RX-API-DMAC7.html)
TW (2) TWI890704B (cg-RX-API-DMAC7.html)
WO (1) WO2021089678A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3154744A1 (en) 2019-11-06 2021-05-14 Sarah FRIEDRICH Glp-1 receptor agonists in dementia
US20230088005A1 (en) * 2020-01-30 2023-03-23 Eli Lilly And Company Therapeutic uses of dulaglutide
EP4262873A4 (en) * 2020-12-16 2024-12-11 The Chinese University of Hong Kong A method for reversing aging brain functional decline
CN118510545A (zh) 2021-12-02 2024-08-16 哥本哈根大学 用于治疗神经退行性疾病的肽-药物缀合物
CN120731085A (zh) * 2023-03-02 2025-09-30 甘李药业股份有限公司 一种glp-1化合物的医药用途
WO2026096637A1 (en) * 2024-10-30 2026-05-07 Tiziana Life Sciences Plc Glp-1 agonists and foralumab combination therapies
CN120131965A (zh) * 2025-04-10 2025-06-13 瓯江实验室 Glp-1受体激动剂治疗阿尔茨海默病的用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
AU3357800A (en) 1999-02-05 2000-08-25 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
EP1411968B1 (en) 2001-07-31 2008-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Glp-1 exendin-4 peptide analogs and uses thereof
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
MX2008001468A (es) 2005-06-30 2008-04-07 Sod Conseils Rech Applic Composiciones farmaceuticas del peptido similar al glucagon-1.
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
EP2066337A2 (en) 2006-08-04 2009-06-10 Amylin Pharmaceuticals, Inc. Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
MX2009002121A (es) 2006-09-07 2009-05-20 Hoffmann La Roche Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico.
US8756102B2 (en) * 2009-11-06 2014-06-17 Edatanetworks Inc. Method, system, and computer program for attracting local and regional businesses to an automated cause marketing environment
US20120329711A1 (en) 2009-12-16 2012-12-27 Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
AU2012241894B2 (en) 2011-04-12 2015-12-03 Novo Nordisk A/S Double-acylated GLP-1 derivatives
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
HUE049152T2 (hu) * 2012-07-01 2020-09-28 Novo Nordisk As Hosszantartó hatású GLP-1 peptidek alkalmazása
WO2015155151A1 (en) 2014-04-07 2015-10-15 Novo Nordisk A/S Double-acylated glp-1 compounds
WO2016198624A1 (en) * 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
US20170112897A1 (en) * 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
AU2016379403B2 (en) * 2015-12-23 2020-03-12 The Johns Hopkins University Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions
US20190142905A1 (en) 2016-04-19 2019-05-16 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
CA3154744A1 (en) 2019-11-06 2021-05-14 Sarah FRIEDRICH Glp-1 receptor agonists in dementia
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses

Also Published As

Publication number Publication date
RS65780B1 (sr) 2024-08-30
WO2021089678A1 (en) 2021-05-14
EP4054620A1 (en) 2022-09-14
EP4414031A3 (en) 2025-02-05
TW202519256A (zh) 2025-05-16
ES2984177T3 (es) 2024-10-29
MA57599B1 (fr) 2024-06-28
MX2022004779A (es) 2022-06-14
TWI923289B (zh) 2026-04-21
JP2023500032A (ja) 2023-01-04
IL291876A (en) 2022-06-01
EP4054620C0 (en) 2024-05-29
BR112022007721A2 (pt) 2022-07-12
KR20220110731A (ko) 2022-08-09
CA3154744A1 (en) 2021-05-14
EP4414031A2 (en) 2024-08-14
TW202118509A (zh) 2021-05-16
US20220280612A1 (en) 2022-09-08
EP4054620B1 (en) 2024-05-29
US12539326B2 (en) 2026-02-03
US20240207364A1 (en) 2024-06-27
TWI890704B (zh) 2025-07-21
HRP20241052T1 (hr) 2024-11-08
US20250099549A1 (en) 2025-03-27
JP7670698B2 (ja) 2025-04-30
PH12022550842A1 (en) 2023-10-09
CN114728042A (zh) 2022-07-08
US20230302094A1 (en) 2023-09-28
AU2020377469A1 (en) 2022-04-28
HUE067514T2 (hu) 2024-10-28
JP2025027130A (ja) 2025-02-26

Similar Documents

Publication Publication Date Title
RS65780B1 (sr) Semaglutid u lečenju alchajmerove demencije
EP3140403A4 (en) Prevention and treatment of alzheimer's disease by genome editing using the crispr/cas system
IL310132B2 (en) Methods of treatment and prevention of alzheimer's disease
SG11202011296VA (en) Compositions and methods for the treatment of parkinson's disease
IL290656A (en) Lorbinectadine in the treatment of malignant mesothelioma
IL288894A (en) Methods for the assessment and treatment of Alzheimer's disease and their applications
EP3773500A4 (en) COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE
IL265911A (en) Epilimod preparations and methods of using them in the treatment of Alzheimer's disease
ZA202101489B (en) Compositions and methods for the treatment of parkinson's disease
PL3413870T3 (pl) Igmezyna do zastosowania do leczenia choroby alzheimera
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
IL254252A0 (en) History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease
PL3352742T3 (pl) Kompozycje zawierające triterpenoidy do leczenia choroby alzheimera i choroby parkinsona
IL276697A (en) 3 Beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders
PL3897655T3 (pl) 3beta-(benzyloksy)-17alfa-metylo-pregn-5-en-20-on do stosowania w leczeniu zaburzeń poznawczych
IL268131A (en) A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of alzheimer's disease
HK40075453B (en) Semaglutide in the treatment of alzheimer's dementia
EP3634979A4 (en) COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S MORBUS
GB201800987D0 (en) tHIRD alzheimer's treatment
GB201800588D0 (en) Third Alzheimer's Treatment
GB201800590D0 (en) Second Alzheimer's Treatment
HK40013419A (en) Apilimod compositions and methods for using same in the treatment of alzheimer's disease
GB201819758D0 (en) Medicine for the treatment of Alzheimer's disease
HK40052061A (en) Methods of treatment and prevention of alzheimer's disease
HK40024508A (en) Compositions and methods for treating alzheimer's disease